• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Illumina

Illumina

Illumina Inc ILMN

Last Price$135.98Day Change (%)1.60%
Open Price$128.49Day Change ($)2.14
Day Range127.10–129.6852-Week Range127.10–242.37

As of Wed 5/4/2016 10:46:00 AM | USD

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  1. Illumina Profit Drops Amid Climbing Expenses

    Illumina Profit Drops Amid Climbing Expenses

  2. Illumina Invests In New Venture Fund

    Illumina Invests In New Venture Fund

  3. Illumina Shares Take Hit on Weakness in Europ

    Illumina Shares Take Hit on Weakness in Europ

  4. UPDATE: Energy stocks rebound, helping the S&P -2-

    UPDATE: Energy stocks rebound, helping the S&P -2-

  5. UPDATE: Energy stocks rebound, helping the S&P 500 generate a gain in April

    UPDATE: Energy stocks rebound, helping the S&P 500 generate a gain in April

  6. UPDATE: Energy stocks rebound, helping the S&P -2-

    UPDATE: Energy stocks rebound, helping the S&P -2-

  7. Illumina Introduces BaseSpace® Informatics Suite to Accelerate Genomic Data Analysis for Sequence Labs

    Illumina Introduces BaseSpace® Informatics Suite to Accelerate Genomic Data Analysis for Sequence Labs

  8. Global Molecular Diagnostics Market Report 2015-2019 - Analysis, Technologies & Forecast - Key Vendors: Abbott, Agendia, bioMerieux - Research and Markets

    Global Molecular Diagnostics Market Report 2015-2019 - Analysis, Technologies & Forecast - Key Vendors: Abbott, Agendia, bioMerieux - Research and Markets

  9. Enanta Announces that AbbVie’s Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting ...

    Enanta Announces that AbbVie’s Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals

  10. Tuttle Tactical Management Weekly Market Notes

    Illumina ILMN reported second-quarter results Tuesday that beat our expectations, and we plan to raise our fair value estimate by several dollars per share. Revenue totaled $84.5 million for the quarter, a 103% increase from the year-ago period, which prompted the firm to significantly raise its ...

12
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.